Since this portion of EVs would less likely add clinically relevant diagnostic values for assessing the risks of bladder cancer, we excluded the use of DTT to remove THP from urine in the CD63-based microchip ELISA for analyzing urinary EVs derived from bladder cancer patients. The gene discussed is CD63; the disease is urinary bladder cancer.